Today UBS Reconfirms a Buy Rating on Pfizer (NYSE:PFE) and a $38.0 Target Price

January 23, 2018 - By Richard Conner

 Today UBS Reconfirms a Buy Rating on Pfizer (NYSE:PFE) and a $38.0 Target Price

Investors sentiment increased to 0.96 in 2017 Q3. Its up 0.02, from 0.94 in 2017Q2. It increased, as 53 investors sold Pfizer Inc. shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported.

Parthenon Lc has invested 1.1% in Pfizer Inc. (NYSE:PFE). Blackhill Cap stated it has 511,201 shares or 3.42% of all its holdings. First American Comml Bank has invested 0.47% in Pfizer Inc. (NYSE:PFE). 110,675 are owned by Benchmark Cap Advsr. Hsbc Hldgs Public Limited Company invested 0.71% of its portfolio in Pfizer Inc. (NYSE:PFE). King Wealth Mngmt Grp Ltd Liability Corporation reported 13,509 shares stake. Forward Mngmt Ltd holds 0.16% in Pfizer Inc. (NYSE:PFE) or 39,304 shares. Acg Wealth holds 23,751 shares. Meristem Limited Liability Partnership holds 0.84% or 58,613 shares in its portfolio. Marco has 0.89% invested in Pfizer Inc. (NYSE:PFE) for 158,977 shares. 23,574 are held by Trust Department Mb Bank & Trust N A. Crestwood Advsr Group Limited Liability holds 0.06% or 19,847 shares in its portfolio. Howland Capital Management Ltd Liability Com stated it has 0.24% of its portfolio in Pfizer Inc. (NYSE:PFE). E&G Advisors L P has 0.9% invested in Pfizer Inc. (NYSE:PFE) for 56,058 shares. New Mexico Educational Retirement Board holds 554,750 shares or 0.94% of its portfolio.

Since August 4, 2017, it had 0 insider purchases, and 10 sales for $16.36 million activity. $3.30M worth of Pfizer Inc. (NYSE:PFE) was sold by READ IAN C on Friday, August 4. $1.34 million worth of Pfizer Inc. (NYSE:PFE) was sold by SUSMAN SALLY on Tuesday, September 12. DAMELIO FRANK A sold $3.21 million worth of stock or 94,409 shares. The insider JOHNSON RADY A sold $296,560. $263,693 worth of stock was sold by OLSON LAURIE J on Monday, August 21.

Pfizer (NYSE:PFE) Rating Reaffirmed

The company has just set a target of $38.0 on Pfizer (NYSE:PFE) shares. This is 2.93 % from the last price. In an analyst note revealed to investors on 1 November, UBS restate their Buy rating on shares of PFE.

Investors sentiment increased to 0.96 in 2017 Q3. Its up 0.02, from 0.94 in 2017Q2. It increased, as 53 investors sold Pfizer Inc. shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported.

Parthenon Lc has invested 1.1% in Pfizer Inc. (NYSE:PFE). Blackhill Cap stated it has 511,201 shares or 3.42% of all its holdings. First American Comml Bank has invested 0.47% in Pfizer Inc. (NYSE:PFE). 110,675 are owned by Benchmark Cap Advsr. Hsbc Hldgs Public Limited Company invested 0.71% of its portfolio in Pfizer Inc. (NYSE:PFE). King Wealth Mngmt Grp Ltd Liability Corporation reported 13,509 shares stake. Forward Mngmt Ltd holds 0.16% in Pfizer Inc. (NYSE:PFE) or 39,304 shares. Acg Wealth holds 23,751 shares. Meristem Limited Liability Partnership holds 0.84% or 58,613 shares in its portfolio. Marco has 0.89% invested in Pfizer Inc. (NYSE:PFE) for 158,977 shares. 23,574 are held by Trust Department Mb Bank & Trust N A. Crestwood Advsr Group Limited Liability holds 0.06% or 19,847 shares in its portfolio. Howland Capital Management Ltd Liability Com stated it has 0.24% of its portfolio in Pfizer Inc. (NYSE:PFE). E&G Advisors L P has 0.9% invested in Pfizer Inc. (NYSE:PFE) for 56,058 shares. New Mexico Educational Retirement Board holds 554,750 shares or 0.94% of its portfolio.

Since August 4, 2017, it had 0 insider purchases, and 10 sales for $16.36 million activity. $3.30M worth of Pfizer Inc. (NYSE:PFE) was sold by READ IAN C on Friday, August 4. $1.34 million worth of Pfizer Inc. (NYSE:PFE) was sold by SUSMAN SALLY on Tuesday, September 12. DAMELIO FRANK A sold $3.21 million worth of stock or 94,409 shares. The insider JOHNSON RADY A sold $296,560. $263,693 worth of stock was sold by OLSON LAURIE J on Monday, August 21.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Among 21 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 11 Hold. Therefore 43% are positive. Pfizer has $54.0 highest and $33.0 lowest target. $38.67’s average target is 4.75% above currents $36.915 stock price. Pfizer had 68 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Outperform” on Thursday, October 19. Cowen & Co upgraded the shares of PFE in report on Tuesday, October 20 to “Outperform” rating. The firm has “Buy” rating given on Tuesday, June 14 by Jefferies. Jefferies maintained the shares of PFE in report on Thursday, August 4 with “Buy” rating. The rating was maintained by Piper Jaffray with “Buy” on Friday, August 14. The firm earned “Buy” rating on Tuesday, September 5 by BMO Capital Markets. S&P Research maintained Pfizer Inc. (NYSE:PFE) on Wednesday, October 28 with “Hold” rating. Cowen & Co maintained the shares of PFE in report on Monday, September 18 with “Buy” rating. The firm has “Hold” rating given on Tuesday, August 1 by BMO Capital Markets. On Tuesday, November 3 the stock rating was maintained by Argus Research with “Buy”.

The stock decreased 0.04% or $0.015 during the last trading session, reaching $36.915. About 7.83M shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since January 23, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on January, 30. They expect $0.56 earnings per share, up 19.15 % or $0.09 from last year’s $0.47 per share. PFE’s profit will be $3.34 billion for 16.48 P/E if the $0.56 EPS becomes a reality. After $0.67 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -16.42 % negative EPS growth.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. The company has market cap of $220.04 billion. It operates through two divisions, Pfizer Innovative Health and Pfizer Essential Health (EH). It has a 22.8 P/E ratio. The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Seekingalpha.com which released: “Hold On To Pfizer In 2018” on December 29, 2017, also Fool.com with their article: “The case for Gilead Sciences” published on January 21, 2018, Streetinsider.com published: “Circle Pharma Reports Publication of Results from Collaboration with Pfizer …” on January 17, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Pfizer: The Best Big Pharma Dividend Stock” published on January 21, 2018 as well as Investorplace.com‘s news article titled: “Why Pfizer Inc. Stock Is One of the Few Safe Drug Stocks” with publication date: December 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: